
Opinion|Videos|September 25, 2024
Optimal Timing and Frequency of Imagining Agents Used in the Detection and Characterization of Oligometastatic Prostate Cancer
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Jaideep Sohi, MD, and Jeremie Calais, MD, conduct a comparative assessment of gallium-based and non-gallium-based imaging agents for their efficacy in detecting and characterizing oligometastatic prostate cancer.
Advertisement
Video content above is prompted by the following:
- How do you determine the optimal timing and frequency of imaging studies using specific agents to monitor oligometastatic disease progression in prostate cancer patients?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Diagnostic Imaging’s Weekly Scan: August 16 — August 22
2
Interventional Radiology in Focus: Emphasizing the Appeal, Advances and Awareness for Interventional Radiology
3
FDA Clears NeuroQuant PET for Assessment of Neurological Conditions
4
Radiology Roundup of FDA News: August 16 — August 22
5










